Lyell Immunopharma Inc Sustainability Reports
Lyell Immunopharma, Inc. is a clinical-stage cell therapy company focused on designing and developing next-generation chimeric antigen receptor (CAR) T-cell therapies to treat patients with solid tumors and hematologic malignancies.
Sector: Manufacturing
Country: United States
Exchange: Nasdaq
1 reports from 2022 to 2022
